August Bioservices

Pre-clinical

Nashville, United StatesFounded 2019augustbio.com

August Bioservices is an innovative CDMO headquartered in Nashville, TN, focused exclusively on sterile injectables. The company offers a fully integrated portfolio of capabilities, including product development, analytical services, and advanced manufacturing, designed to support clients from early-phase clinical trials to commercial supply. With a leadership team boasting decades of collective experience in aseptic manufacturing and a commitment to quality and collaboration, August Bio aims to be an indispensable partner in bringing life-altering therapies to patients faster.

Founded

2019

Focus

BiologicsContract Manufacturing

AI Company Overview

Technology Platform

August Bioservices provides an integrated CDMO service platform for sterile injectables, encompassing process development, analytical testing, and advanced aseptic manufacturing using state-of-the-art flexible filling lines and single-use technology.

Funding History

Total raised: $28M

Series A$23MUndisclosedSep 15, 2022

Seed$5MUndisclosedJun 15, 2021

Opportunities

The company is positioned to capitalize on the robust growth in biologics and complex injectable drug development, where outsourcing is standard.

Its US-based, integrated model offers a compelling value proposition for biotechs seeking speed, quality, and regulatory assurance.

Expansion into adjacent service areas like aseptic manufacturing for advanced therapies (e.g., cell & gene) represents a significant future opportunity.

Risk Factors

Key risks include high dependence on winning and retaining client projects in a competitive CDMO market, the capital-intensive nature of maintaining state-of-the-art aseptic facilities, and significant regulatory exposure where any compliance failure could severely impact operations and reputation.

Competitive Landscape

August Bioservices competes with large, diversified CDMOs (e.g., Catalent, Lonza) and specialized injectable manufacturers. Its differentiation lies in its exclusive focus on sterile injectables, a collaborative partnership approach, and advanced, flexible manufacturing technology housed in a single, integrated US site, aiming to reduce complexity for clients.